Atossa Therapeutics, Inc.ATOSNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank14
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P14
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
2024-18.56%
202314.92%
202263.77%
202139.38%
2020-7.35%
201969.41%
201880.83%
2017202.18%
2016-67.35%
2015-8.45%